Source: http://www.google.com/patents/US8124721
Timestamp: 2015-01-26 02:31:27
Document Index: 782266799

Matched Legal Cases: ['application No. 07719467', 'application No. 10003191', 'application No. 07719467', 'application No. 07719467', 'application No. 06790808', 'application No. 10003191', 'application No. 190601']

Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS20030119750Apr 19, 2002Jun 26, 2003Hans-Ulrich DemuthUse of dipeptidyl peptidase IV inhibitorsUS20030130199Jun 13, 2002Jul 10, 2003Von Hoersten StephanDipeptidyl peptidase IV inhibitors and their uses as anti-cancer agentsUS20030176357Jul 23, 2002Sep 18, 2003Pospisilik Andrew J.Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levelsUS20040235049May 27, 2002Nov 25, 2004Oleg MelnykDevice for presentation of polypeptides able to be used as a chip for miniaturised detection of moleculesUS20050069911Feb 5, 2004Mar 31, 2005Engeneos, Inc.Proteome epitope tags and methods of use thereof in protein modification analysisUS20050191296Oct 4, 2004Sep 1, 2005Raymond KaempferBroad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereofUS20080118525Apr 3, 2007May 22, 2008Oreola DoniniNovel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunityUS20090062512Jun 18, 2008Mar 5, 2009Hildebrand William HComparative ligand mapping from MHC class I positive cellsUS20090186824Mar 16, 2009Jul 23, 2009Oreola DoniniNovel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunityEP0045665A1Aug 5, 1981Feb 10, 1982Aktiebolaget H�ssleEnzyme inhibitorsWO2001031019A2Oct 30, 2000May 3, 2001Chiron SpaNeisserial antigenic peptidesWO2003002596A2Jun 27, 2002Jan 9, 2003Hans-Ulrich DemuthUse of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disordersWO2003048383A2Dec 2, 2002Jun 12, 2003Dawn BowdishEffectors of innate immunityWO2003063759A2Jan 30, 2003Aug 7, 2003Ann AvronHsp peptides and analogs for modulation of immune responses via antigen presenting cellsWO2003106491A2Jun 18, 2003Dec 24, 2003Cepep AbCell penetrating peptidesWO2004031211A2Oct 3, 2003Apr 15, 2004Epimmune IncHla binding peptides and their usesWO2005025607A1Sep 10, 2004Mar 24, 2005Univ British ColumbiaMethods of stimulating innate immunity using cationic peptidesWO2005026204A2Sep 13, 2004Mar 24, 2005Hoegenhaug Hans-Henrik KristenSynthetic antimicrobial polypeptidesWO2005081628A2Feb 20, 2005Sep 9, 2005Chay 13 Medical Res Group N VCasein derived peptides and therapeutic uses thereofWO2006005190A1Jul 14, 2005Jan 19, 2006Danika GoosneyMethod of screening for protection from microbial infectionWO2006015886A1Aug 9, 2005Feb 16, 2006Herche Medicale Inserm Inst NaAngiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2WO2006038208A2Jul 12, 2005Apr 13, 2006Ct Medical Res Fund Of Tel AviAgents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatmentWO2006050611A1Nov 14, 2005May 18, 2006Robert E W HancockAntimicrobial peptidesWO2006114478A1Apr 25, 2006Nov 2, 2006Mathias BergmanDiagnostic and therapeutic agentsWO2008040111A1Apr 3, 2007Apr 10, 2008Inimex Pharmaceuticals IncNovel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunityNon-Patent CitationsReference1Applicants' response dated Jan. 6, 2011 to Communication dated Jul. 6, 2010 in corresponding EP patent application No. 07719467.8.2Augustyns K et al: "The . . . " Current Medicinal Chemistry Bentham Science Publishers BV BE, vol. 12, No. 8, Jan. 1, 2005 pp. 971-998 XP009066443; ISSN 0929-8673.3Blazquez M V, et al. "Selective decrease of CD26 expression in T cells from HIV-1-infected individuals." J. Immunol. Nov. 1, 1992; 149(9):3073-7.4Boris Weinstein, "Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins" (Marcel Dekker, Inc., New York, 1983), pp. 267-357.5Bowie et al, Deciphering the message in protein sequences: tolerance to amino acid substitutions, Science, 247(4948):1306-10 (Mar. 1990).6Burgess et al, Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue, Journal of Cell Biology, 111:2129-38 (Nov. 1990).7 *Christopherson, et al. "Cell Surface Peptidase CD26/Dipeptidylpeptidase IV Regulates CXCL12/Stromal Cell-Derived Factor-1alpha-Mediated Chemotaxis of Human Cord Blood CD34+ Progenitor Cells" (The Journal of Immunology, 2002, 169: 7000-7008).8 *Christopherson, et al. "Cell Surface Peptidase CD26/Dipeptidylpeptidase IV Regulates CXCL12/Stromal Cell-Derived Factor-1α-Mediated Chemotaxis of Human Cord Blood CD34+ Progenitor Cells" (The Journal of Immunology, 2002, 169: 7000-7008).9Colman, Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, 145:33-36 (Jan. 1994).10Communication dated Aug. 4, 2010 including partial European Search Report issued in related EP patent application No. 10003191.3.11Communication dated Jul. 6, 2010 issued in corresponding European patent application No. 07719467.8.12Communication dated Jun. 18, 2010 including Extended European Search Report issued in corresponding EP patent application No. 07719467.8.13Communication dated Jun. 26, 2009 including Extended European Search Report issued in related EP patent application No. 06790808.7.14Communication dated Nov. 29, 2010 including Extended European Search Report issued in related EP patent application No. 10003191.3.15Constantinescu C S, et al. "A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis." J Neurol Sci. Jun. 1995; 130(2):178-82.16Durinx C et al., (2001) Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med. 39(2):155-9.17Eguchi K, et al. "Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease." J Immunol Jun. 15, 1989; 142(12):4233-40.18Evans BE, et al. "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonist." J Med Chem. Jul. 1987;30(7):1229-1239.19Fotouhi et al, Potent peptide inhibitors of stromelysin based on the prodomain region of matrix metalloproteinases, Journal of Biological Chemistry, 269(48):30227-31 (Dec. 1994).20Genbank Accession No. CAD45512, accessed Nov. 14, 2011.21Hinke et al., "Dipeptidyl Peptibase IV (DPIV/CD26) Degradation of Glucagon", J. Biol. Chem. 275(6): 3827-3834, 2000.22Houghten et al, New approaches to Immunization, Vaccines 86, Cold Spring Harbor Laboratory, p. 21-25, 1986.23International Preliminary Report on Patentability dated Apr. 7, 2009 issued in related international patent application No. PCT/CA2007/000537.24International Search Report dated Jul. 20, 2007 issued in related international patent application No. PCT/CA2007/000537.25Iwata et al., "CD26/Dipeptidyl Peptibase IV Differentially Regulates the Chemotaxis of T Cells and Monocytes Toward RANTES . . . ", Int. Immunol. 11: 417-426, 1999.26 *Iwata S. et al. "CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response" International Immunology, vol. 11, No. 3, pp. 417-426, 1999.27Kasprzykowski et al, Peptidyl Diazomethylketones as Cysteine Protease Inhibitors Structurally based Upon the Inhibitory Centers of Cystatins, Polish J. Chem, 75:831-837 (Feb. 2001).28Katoh et al, Discrimination between alpha-amylase isozymes with anti-peptide antibodies, Chemical Engineering Journal, 65(2):105-8 (May 1997).29Katoh et al, Discrimination between α-amylase isozymes with anti-peptide antibodies, Chemical Engineering Journal, 65(2):105-8 (May 1997).30Kelsen et al., "The Chemokine Receptor CXCR3 and Its Splice Variant are Expressed in Human Airway Epithelial Cells", Am. J. Physiol. Lung Cell Mol. Physiol 287: L584, 2004.31 *Lambeir et al. "Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family" The Journal of Biological Chemistry 276(32):29839-29845, 2001.32Lau, Y. E. et al, "Interaction and Cellular Localization of the Human Host Defence . . . ", Infection and Immunity, Jan. 2005, vol. 73, No. 1, pp. 583-591, ISSN 0019-9567.33Lazar et al, Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities, Molecular and Cellular Biology, 8(3):1247-52 (Mar. 1988).34Marguet et al., "Enhanced Insulin Secretion and Improved Glucose Tolerance in Mice Lacking CD26", PNAS 97(12): 6874-6879, 2000.35Morimoto C, Schlossman S F. The structure and function of CD26 in the the T-cell immune response. Immunol. Review. 1998, 161: 55-70.36Morley, "Modulation of the Action of Regulatory Peptides by Structural Modification", (General Review) Trends Pharm. Sci. pp. 463-468 (1980).37Nakao H, et al. "Increment of Ta1 positive cells in peripheral blood from patients with rheumatoid arthritis." J Rheumatol. Jul. 1989; 16(7):904-10.38Ng et al, Predicting deleterious amino acid substitutions, Genome Research, 11(5):863-74 (May 2001).39Nishikawa Y, et al. [Adenosine deaminase isoenzymes in patients with Graves' disease] Rinsho Byori. Oct. 1995,43(10):1057-60. [Article in Japanese].40Nomura et al, Purification of angiotensin I-converting enzyme inhibitors in pelagic thresher Alopias pelagicus muscle hydrolysate and viscera extracts, Fisheries Science, 68(4):954-6 (2002).41Office Action dated Dec. 17, 2008 issued in related U.S. Appl. No. 11/730,695.42Office Action dated Sep. 15, 2011 issued in corresponding Israeli patent application No. 190601.43Oravecz et al., "Regulation of the Receptor Specificity and Function of the Chemokine RANTES by Dipeptidyl Peptibase IV (CD26)-Mediated Cleavage", J Exp Med 186: 1865, 1997.44Oravecz T, et al. "CD26 expression correlates with entry, replication . . . " Nat Med Sep. 1995; 1(9):919-26 Comment in: Nat. Med. Sep. 1995; 1(9):881-2.45Paton et al, Phylogeny and evolution of basils and allies (Ocimeae, Labiatae) based on three plastid DNA regions, Molecular phylogenetics and Evolution, 31:277-299 (Apr. 2004).46Schols D, et al. "CD26-processed RANTES (3-68), but not intact RANTES, . . . " Antiviral Res. Oct. 1998; 39(3):175-87. Erratum in: Antiviral Res Jan. 1999; 40(3):189-90.47Shoukry Naglaa H et al: "Conserved hierarchy . . . infections." Journal of Immunology, vol. 172, No. 1, Jan. 1, 2004, pp. 483-492, XP002592693 ISSN: 0022-176.48Stecca B A, et al. "Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma." J Hepatol. Aug. 1997; 27(2):337-45.49STN Search Results, Apr. 15, 2011 (33 pages).50STN Search Results, Apr. 15, 2011 (4 pages).51STN Search Results, Mar. 24, 2011 (146 pages).52STN Search Results, Mar. 24, 2011 (43 pages).53Tam JP, Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system, Proceedings of the National Academy of Sciences USA, 85(15):5409-13 (Aug. 1988).54Tanabe, H. et al, "Paneth Cell Alpha-Defensins From Rhesus Macaque Small Intestine", Infection and Immunity, Mar. 2004, vol. 72, No. 3, pp. 1470-1478, ISSN 0019-9567.55Tanaka, S., et al., Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology 1998, 40: 21-26.56Tanaka, S., et al.,: Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J. Immunopharmacol 1997, 19:15-24.57Vanham G, et al. "Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of . . . " J Acquir Immune Defic Syndr. Jul. 1993; 6(7): 749-57.58Wrenger Sabine et al: "The N-terminal . . . " Journal of Biological Chemistry, vol. 272, No. 48, Nov. 28, 1997, pp. 30283-30288, XP002531563 ISSN: 0021-9258.59Wrenger Sabine et al: "The N-terminal X-X-Pro sequence of the HIV-1 Tat protein . . . T cells" FEBS Letters, vol. 383, No. 3, 1996, pp. 145-149, XP002531562; ISSN: 0014-5793.60Yamamoto et al, Biogenic peptides and their potential use, Current Pharmaceutical Design, 9(16):1345-55 (2003).* Cited by examinerClassifications U.S. Classification530/300, 424/184.1International ClassificationC07K14/00, A61K39/00Cooperative ClassificationC07K7/06, G01N2800/52, C07K7/08, A61K38/00, G01N33/569, C07K7/00, C12Q1/37European ClassificationC07K7/08, C07K7/06, C12Q1/37, G01N33/569Legal EventsDateCodeEventDescriptionJan 14, 2013ASAssignmentFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INIMEX PHARMACEUTICALS, INC.;REEL/FRAME:029619/0868Owner name: SOLIGENIX, INC., NEW JERSEYEffective date: 20121130Jul 3, 2012CCCertificate of correctionAug 30, 2011ASAssignmentFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DONINI, OREOLA;ROZEK, ANNETT;LENTZ, SHANNON WAYNE;SIGNING DATES FROM 20080427 TO 20080506;REEL/FRAME:026828/0311Owner name: INIMEX PHARMACEUTICALS INC., CANADARotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services